Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00731302 · ClinicalTrials.gov registry record · Phase 1
Aspirin Resistance in Systemic Lupus Erythematosus (SLE)
A Phase 1 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT00731302 is a Phase 1 study that has completed, run by Vanderbilt University. The registered enrollment target is 70 participants.
The verdict
NCT00731302, a Phase 1 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
This study examine whether patients with lupus respond to aspirin , and if not, if that is related to inflammation. We examine the ability of aspirin to inhibit the production of thromboxane in patients with lupus and controls and see if aspirin insensitive thromboxane production is inhibited by meloxicam.
Interventions
- DRUG aspirin and meloxicam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2005-04 |
| Est. Completion | 2017-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00731302
The ClinicalTrials.gov registry entry for NCT00731302 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aspirin and meloxicam is the first listed.
NCT00731302 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00731302 about?
NCT00731302 is a clinical study titled "Aspirin Resistance in Systemic Lupus Erythematosus (SLE)". This study examine whether patients with lupus respond to aspirin , and if not, if that is related to inflammation. We examine the ability of aspirin to inhibit the production of thromboxane in patients with lupus and controls and see if aspirin insensitive thromboxane production is inhibited by mel...
What is the current status of trial NCT00731302?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2005-04. Estimated completion is 2017-04.
What interventions are being tested in trial NCT00731302?
The interventions under investigation include: aspirin and meloxicam (DRUG).
Who is sponsoring clinical trial NCT00731302?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.